Q3 2025 Abcellera Biologics Inc Earnings Call Transcript

Nov 6, 2025 / 10:00 PM GMT

Release Date Price: $4.53 (-3.41%)

Transcript 10-Q8-K

Key Points

Positve

AbCellera Biologics Inc (ABCL) has successfully transitioned from a platform company to a clinical-stage biotech, with phase one clinical trials for ABCL 635 and ABCL 575 underway.
The company has initiated activities at its new clinical manufacturing facility and completed substantial platform investments.
AbCellera Biologics Inc (ABCL) maintains a strong liquidity position with approximately $680 million in available liquidity, including cash, cash equivalents, and committed government funding.
The appointment of Dr. Sarah Numberg as Chief Medical Officer brings over 20 years of clinical drug development experience to the company.
The company is on track to advance at least one more development candidate into IND-enabling studies by the end of the year.

Negative

Revenue for the quarter was $9 million, which, although an increase from the previous year, is still relatively low.
Research and development expenses increased significantly to $55 million, reflecting a focus on internal and co-development programs.
The company reported a net loss of approximately $57 million for the quarter, an increase from the previous year's loss.
There is a trend of decreasing research fee revenue as the company focuses more on its internal pipeline.
The transition from partner-initiated programs to AbCellera-led development has resulted in some delays in clinical progression.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABCL.OQ - Abcellera Biologics Inc
Q3 2025 Abcellera Biologics Inc Earnings Call
Nov 06, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Appelerer's 3rd quarter 2025 business update conference call. My name is Cameron and I'll facilitate the audio portion of today's interactive broadcast. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question. Please press followed by 1 on your telephone keypad. And if you are having any issues during the call, please press followed by 0 on your telephone keypad. At this time, I would like to turn the call over to Trent Steinard, Appelerer's chief legal and compliance officer. You may proceed.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.